SIMIAN RETROVIRUS VACCINE FOR NON-HUMAN PRIMATES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本项目的目标是测试两种候选疫苗，用于保护猕猴免受猿猴D型逆转录病毒（SRV）血清型2的侵害。 如果成功，这可能有助于预防猕猴中常见的自发性逆转录病毒诱导的免疫抑制疾病。 SRV-2感染在野生环境中普遍存在，在圈养猕猴中也很常见，并能在猿猴中引起AIDS样疾病。 通过体液（尿液或血液）迅速传播，SRV-2可引起野生和圈养猕猴群体的地方性感染。 本研究目前有8只动物。 在第1阶段，两只动物将IV接种从Tulane Primate Center内部来源获得的SRV。 血液样本、淋巴结和肠活检以及唾液对SRV呈阴性。 从加州大学戴维斯分校获得的另一份SRV贮备液用于对2只猴进行复乳。 所有接种后的病毒感染和致病性PCR检测均为阳性。 在第2阶段，所有动物将用于疫苗研究VSV加强疫苗策略。 用VSV-SRV env/gag杂交病毒免疫4只恒河猴。另外2只疫苗阴性猴和4只免疫猴用SRV-2静脉内攻毒。 所有对照猴的病毒血症PCR均为阳性，所有4只免疫猴均得到完全保护。 因此，VSV免疫能够诱导针对SRV-2的灭菌免疫。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this project is to test two candidate vaccines for protection of macaques against Simian Type D Retrovirus (SRV) serotype 2. If successful, this may be helpful in preventing a common spontaneous retrovirus induced immunosuppressive disease in macaques. Infection with SRV-2 is prevalent in wild and has been common in captive macaques and is capable of causing an AIDS like disease in simians. Rapidly spread through body fluids (salvia or blood), SRV-2 can cause an endemic infection of wild and captive macaques colonies. There are currently 8 animals on this study. In phase 1, two animals will be inoculated IV with SRV obtained from in house sources at the Tulane Primate Center. Blood samples, lymph node and intestinal biopsies and saliva were negative for SRV. Another stock of SRV had been obtained from the University of California Davis was used to re-inoculate the 2 monkeys. All post-inoculation SRV infection and pathogenesis were positive for infection by PCR. In phase 2, all animals will be used in vaccine study VSV boosting vaccine strategy. Four rhesus macaques were immunized with VSV-SRV env/gag hybrid viruses. Two additional vaccine negative monkeys and 4 immunized monkeys were challenged intravenously with SRV-2. All control monkeys were positive by PCR for viremia and all 4 immunized monkeys were completely protected. Therefore, VSV-immunization was capable of inducing sterilizing immunity against SRV-2.